Under the Paperwork Reduction Act of 1995, no persons are required to

| INFORMATION DISCLOSURE |
|---|
| STATEMENT BY APPLICANT |
| (Not for submission under 37 CFR 1.99) |
| |

| Application Number | | 10609133 | | |
|----------------------|-------|-------------------|--|--|
| Filing Date | | 2003-06-26 | | |
| First Named Inventor | Mans | oor Sarfarazi | | |
| Art Unit | | 1634 | | |
| Examiner Name | Jehar | nne Souaya Sitton | | |
| Attorney Docket Numb | er | UCT-0046-P2 | | |

| | | | | | U.S. | PATENTS | | | Remove | |
|-----------------------|------------|--|------------------------------|-----------------|---------------------------|-------------------------------|---|--------------------|---|----|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue E | Date | Name of Pate of cited Docu | entee or Applicant ment | Releva | Columns,Lines when ant Passages or Rele s Appear | |
| | 1 | | | | | | | | | |
| If you wis | h to a | i dadditional U.S. Pater | nt citatio | n inform | ation pl | ease click the | Add button. | | Add | |
| | | | U.S.P | ATENT | APPLI | CATION PUBL | LICATIONS | | Remove | |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publica Date | tion | | | | Columns,Lines when ant Passages or Rele s Appear | |
| | 1 | | | | | | | | | |
| If you wisl | h to a | dd additional U.S. Publi | | , | | , | | d buttor | | |
| | | | | FOREIG | SN PAT | ENT DOCUM | ENTS | | Remove | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | | Kind Code ⁴ | Publication Date | Name of Patente Applicant of cited Document | e or | Pages,Columns,Line where Relevant Passages or Relevar Figures Appear | Ts |
| | 1 | | | | | | | | | |
| If you wis | h to a | l dd additional Foreign P | atent Do | cument | citation | information pl | lease click the Add | button | Add | - |
| | | | NON | I-PATE | NT LITE | RATURE DO | CUMENTS | | Remove | |
| Examiner Initials* | Cite No | Include name of the a (book, magazine, jour publisher, city and/or | nal, seria | al, symp | osium, | catalog, etc), o | the article (when a date, pages(s), vol | ppropri ume-iss | ate), title of the item sue number(s), | Тъ |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10609133 |
|------------------------|-------|------------------|
| Filing Date | | 2003-06-26 |
| First Named Inventor | Mans | oor Sarfarazi |
| Art Unit | | 1634 |
| Examiner Name | Jehar | ne Souaya Sitton |
| Attorney Docket Number | | UCT-0046-P2 |

| | 1 | | pean Search Report; Application No. 02794367,9-2402 PCT/US0. 1,84869, 4 pages | 241116; Date 08 08.06 | 3, Reference | | | | |
|------------|---|---|--|-----------------------|------------------|--|--|--|--|
| | 2 | | ABASE EMBL [Online]; "Macaca Fascicularis Brain dDNA, cione: Q N); mRNA; NM_001008211"; 1 March 2001; XP002390970 | f1A-13191; Similar to | Human Optineurin | | | | |
| | 3 | | PFAFAZI M: "Recent Advances in Molecular Genetics of Glaucomes" Human Molecular Genetics, Cxford lersity Press, Surrey, GB; Vol. 6; pp 1967-1977; 1997; ISSN: 0964-996; XP002065987 | | | | | | |
| | 4 | LI Y ET AL: "Interaction of Adenovirus E3 14.7-ADa Protein with a Novel Tumor Necrosis Factor Alpha-Inducible Cealuse Protein Containing Leucine-Zipper Domains", Molecular and Cellular Biology, Washington, DC, US; Vol. 18; pp 1601-1610, March 1969; SSA: 2767-7366, WPG2056667 | | | | | | | |
| | 5 LIBBY RICHARD T ET AL. "Complex Genetics of Glaucoma Susciptibility.", Annual Review of Genomics and Human Genetics; Vol. 6; pp 15-44; 2005; ISSN: 1527-8204; XP002390868 | | | | | | | | |
| If you wis | h to a | dd add | ditional non-patent literature document citation information p | lease click the Add | button Add | | | | |
| | | | EXAMINER SIGNATURE | | | | | | |
| Examiner | r Signa | ature | | Date Considered | | | | | |

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| | Application Number | | 10609133 | | |
|---------------------------|--------------------|--|-------------------|--|--|
| Filing Date | | | 2003-06-26 | | |
| First Named Inventor Mans | | | oor Sarfarazi | | |
| Art Unit | | | 1634 | | |
| Examiner Name Jehan | | | nne Souaya Sitton | | |
| Attorney Docket Number | | | UCT-0046-P2 | | |

CERTIFICATION STATEMENT

| Diagra con | 27 | CED 4 | 07 | and 1 | 09 to | make the | opproprieto | selection(s): |
|------------|----|-------|----|-------|-------|----------|-------------|---------------|
| | | | | | | | | |

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

| Signature | /Karen A. LeCuyer/ | Date (YYYY-MM-DD) | 2006-11-03 |
|------------|--------------------|---------------------|------------|
| Name/Print | Karen A. LeCuver | Registration Number | 51.928 |

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.